SCHEMBL3449251

SCHEMBL3449251

CON(C)C(=O)c1cnoc1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
RAB9A P51151 3/20 0.42
DHODH Q02127 3/20 0.39
NPC1 O15118 2/20 0.39
GMNN O75496 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
HTR1A P08908 1/20 0.39
THRB P10828 1/20 0.39
PIM1 P11309 1/20 0.39
CYP2C9 P11712 1/20 0.39
MAOA P21397 1/20 0.39
SLC6A2 P23975 1/20 0.39
HTR2A P28223 1/20 0.39
AGTR1 P30556 1/20 0.39
CCKBR P32239 1/20 0.39
MC4R P32245 1/20 0.39
CYP2C19 P33261 1/20 0.39
THPO P40225 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8572688 0.83 LMNA (0.45) LMNARAB9ADHODHNPC1GMNN
SCHEMBL353732 0.77 LMNA (0.41) LMNARAB9ADHODHNPC1GMNN
SCHEMBL9393482 0.76 LMNA (0.43) LMNARAB9ADHODHNPC1GMNN
SCHEMBL27344723 0.76 RAB9A (0.47) LMNARAB9ADHODHNPC1GMNN
SCHEMBL13815776 0.76 RAB9A (0.55) LMNARAB9ADHODHNPC1GMNN
SCHEMBL27969576 0.74 LMNA (0.50) LMNARAB9ADHODHNPC1GMNN
SCHEMBL31021815 0.73 ICAM1 (0.35) RAB9ASLC6A3MLYCDICAM1SELE
SCHEMBL439222 0.72
SCHEMBL29791455 0.71 GPBAR1 (0.54) RAB9ANPC1CYP3A4CYP2C19
SCHEMBL1023500 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD LMNA 1717/4885RAB9A 2449/4885DHODH 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.